Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
Status:
RECRUITING
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to better understand how hormone suppression with Relugolix Combination-Therapy (CT) affects pelvic pain, inflammation, and pain sensitivity in women with moderate-to-severe endometriosis associated pelvic pain.
Phase:
PHASE3
Details
Lead Sponsor:
University of Michigan
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)